Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CG Oncology

Request full access

Focused on developing bladder cancer therapeutics

Dallas, United StatesFounded 2010Biotech & Life Sciences

About CG Oncology

CG Oncology is a late-stage biopharmaceutical company developing bladder-sparing immunotherapies for patients with urologic cancers. Its lead candidate, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy delivered directly into the bladder (intravesically) for non-muscle invasive bladder cancer (NMIBC). The company was formerly known as Cold Genesys.

Cretostimogene holds FDA Fast Track and Breakthrough Therapy designations. In the pivotal Phase 3 BOND-003 trial (Cohort C) in high-risk NMIBC that no longer responds to standard BCG treatment, it showed a 41.8% complete response rate at 24 months. The results were published in The Lancet Oncology in July 2026. The company has begun a rolling Biologics License Application (BLA) to the FDA for this indication and expects to complete it in Q4 2026. A Phase 3 trial in intermediate-risk NMIBC, PIVOT-006, has topline results expected soon, and the Phase 2 CORE-008 trial is evaluating patients previously treated with BCG.

CG Oncology went public on Nasdaq (CGON) in January 2024, raising $380M, and is headquartered in Dallas, Texas. Cretostimogene is investigational and not yet approved by any regulatory agency.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2024

CG Oncology in the Dallas ecosystem

Live from Dealroom

The CG Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Ally Bridge Group
  • WI Harper Group

Series B and later16 investors entered at this stage

Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Dallas HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$6M

2 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See CG Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.